RayKnowChina Research Map
Shortlist0

Not yet recruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Eye & ENT Hospital of Fudan University; 3 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 4

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorEye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院ShanghaiHospital page
  2. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  3. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  4. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04215510, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Diagnosed of recurrent nasopharyngeal carcinoma by pathology or imaging study;

    Inclusion criterion 1

  3. Stage T1 or T2 according to AJCC 8th edition ;

    Inclusion criterion 2

  4. previously received 1 course of radiotherapy;

    Inclusion criterion 5

  5. ECOG score 0 or 1;

    Inclusion criterion 9

  6. Female patients who are at pregnancy or lactation.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04215510, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Diagnosed of recurrent nasopharyngeal carcinoma by pathology or imaging study;
  • Stage T1 or T2 according to AJCC 8th edition ;
  • Aged 18 to 70 years;
  • Without metastasis;
  • previously received 1 course of radiotherapy;
  • Without radiotherapy within 1 year, without local treatment for recurrent disease;
  • Surgical resectable and IMRT suitable;
  • If regional recurrence presented, regional lesion can be treated with local treatments.
  • ECOG score 0 or 1;
  • Sufficient organ function;
  • Acceptable approach of contraception.

Exclusion Criteria:

  • Refuse to sign inform consent;
  • Radiation encephalopathy or leptomeningeal disease (LMD);
  • History of radioactive particle planting;
  • Have uncontrolled intercurrent illnesses which will interfere with the ability to undergo therapy;
  • With prior malignancy (excluding adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer );
  • Any contradiction to surgery;
  • Have any co-existing condition that would preclude full compliance or safety with the study;
  • Presence of a significant neurological or psychiatric disease, including dementia and seizures;
  • Uncontrolled infectious diseases;
  • Female patients who are at pregnancy or lactation.
  • Without personal freedom or independent civil capacity.
  • With serious autoimmune disease.
  • Participants of other interventional clinical trial.

Quoted from ClinicalTrials.gov, NCT04215510, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04215510, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04215510